Canrenone

DRUG4 trials

Sponsors

Policlinico San Donato S.p.A., Heart Care Foundation, University of Pavia, National Institute of Cardiology, Warsaw, Poland

Conditions

Atrial Fibrillation, ParoxysmalCardiac Heart Failure PatientsHeart Failure

Phase 3

Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study

CompletedNCT00403910

Heart Care FoundationHeart Failure

Start: 2002-09-30End: 2006-07-31Target: 500Updated: 2021-02-03

Phase 4

Clinical Efficacy of Potassium Canrenoate in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation.

National Institute of Cardiology, Warsaw, PolandAtrial Fibrillation, Paroxysmal

Start: 2018-06-30End: 2020-12-31Target: 80Updated: 2018-05-25

Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (PopS-HF Trial)

Not yet recruitingCTIS2025-520660-18-00

Policlinico San Donato S.p.A.Heart Failure

Target: 368Updated: 2025-11-17

Unknown Phase

Canrenone Effects on Cardiovascular Mortality in Patients With Congestive Heart Failure (the Coffee-it Study)

CompletedNCT03263962

University of PaviaCardiac Heart Failure Patients

Start: 2017-07-13End: 2017-11-30Updated: 2018-02-05

Related Papers

Clinical Efficacy of Canrenone in Restoring Sinus Rhythm in Patients With Atrial Fibrillation—A Pilot, Randomized, Double-Blind Study

Journal of Cardiovascular Pharmacology and Therapeutics2025-01-01

Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial).

2020-05-125 citations